Matthew D Cheney1, Yen-Lin Chen2, Ruth Lim3, Barbara K Winrich2, Anca L Grosu2, Alexei V Trofimov2, Nicolas Depauw4, Helen A Shih2, Joseph H Schwab5, Francis J Hornicek5, Thomas F DeLaney2. 1. Harvard Radiation Oncology Program, Boston, Massachusetts. Electronic address: mcheney@lroc.harvard.edu. 2. Department of Radiation Oncology, Massachusetts General Hospital, Boston, Massachusetts. 3. Department of Diagnostic Radiology, Massachusetts General Hospital, Boston, Massachusetts. 4. Department of Radiation Oncology, Massachusetts General Hospital, Boston, Massachusetts; Centre of Medical Radiation Physics, University of Wollongong, Wollongong, NSW, Australia. 5. Department of Orthopedic Oncology, Massachusetts General Hospital, Boston, Massachusetts.
Abstract
PURPOSE: To investigate [18F]-fluoromisonidazole positron emission tomography/computed tomography (FMISO-PET/CT) detection of targetable hypoxic subvolumes (HSVs) in chordoma of the mobile or sacrococcygeal spine. METHODS AND MATERIALS: A prospective, pilot study of 20 patients with primary or locally recurrent chordoma of the mobile or sacrococcygeal spine treated with proton or combined proton/photon radiation therapy (RT) with or without surgery was completed. The FMISO-PET/CT was performed before RT and after 19.8-34.2 GyRBE (relative biologic effectiveness). Gross tumor volumes were delineated and HSVs defined including voxels with standardized uptake values ≥1.4 times the muscle mean. Clinical characteristics and treatments received were compared between patients with and without HSVs. RESULTS: The FMISO-PET/CT detected HSVs in 12 of 20 patients (60%). Baseline and interval HSV spatial concordance varied (0%-94%). Eight HSVs were sufficiently large (≥5 cm(3)) to potentially allow an intensity modulated proton therapy boost. Patients with HSVs had significantly larger gross tumor volumes (median 410.0 cm(3) vs 63.4 cm(3); P=.02) and were significantly more likely to have stage T2 tumors (5 of 12 vs 0 of 8; P=.04). After a median follow-up of 1.8 years (range, 0.2-4.4 years), a local recurrence has yet to be observed. Three patients developed metastatic disease, 2 with HSVs. CONCLUSIONS: Detection of targetable HSVs by FMISO-PET/CT within patients undergoing RT with or without surgery for treatment of chordoma of the mobile and sacrococcygeal spine is feasible. The study's inability to attribute interval HSV changes to treatment, rapidly changing hypoxic physiology, or imaging inconsistencies is a limitation. Further study of double-baseline FMISO-PET/CT and hypoxia-directed RT dose escalation, particularly in patients at high risk for local recurrence, is warranted.
PURPOSE: To investigate [18F]-fluoromisonidazole positron emission tomography/computed tomography (FMISO-PET/CT) detection of targetable hypoxic subvolumes (HSVs) in chordoma of the mobile or sacrococcygeal spine. METHODS AND MATERIALS: A prospective, pilot study of 20 patients with primary or locally recurrent chordoma of the mobile or sacrococcygeal spine treated with proton or combined proton/photon radiation therapy (RT) with or without surgery was completed. The FMISO-PET/CT was performed before RT and after 19.8-34.2 GyRBE (relative biologic effectiveness). Gross tumor volumes were delineated and HSVs defined including voxels with standardized uptake values ≥1.4 times the muscle mean. Clinical characteristics and treatments received were compared between patients with and without HSVs. RESULTS: The FMISO-PET/CT detected HSVs in 12 of 20 patients (60%). Baseline and interval HSV spatial concordance varied (0%-94%). Eight HSVs were sufficiently large (≥5 cm(3)) to potentially allow an intensity modulated proton therapy boost. Patients with HSVs had significantly larger gross tumor volumes (median 410.0 cm(3) vs 63.4 cm(3); P=.02) and were significantly more likely to have stage T2 tumors (5 of 12 vs 0 of 8; P=.04). After a median follow-up of 1.8 years (range, 0.2-4.4 years), a local recurrence has yet to be observed. Three patients developed metastatic disease, 2 with HSVs. CONCLUSIONS: Detection of targetable HSVs by FMISO-PET/CT within patients undergoing RT with or without surgery for treatment of chordoma of the mobile and sacrococcygeal spine is feasible. The study's inability to attribute interval HSV changes to treatment, rapidly changing hypoxic physiology, or imaging inconsistencies is a limitation. Further study of double-baseline FMISO-PET/CT and hypoxia-directed RT dose escalation, particularly in patients at high risk for local recurrence, is warranted.
Authors: Lily Park; Thomas F Delaney; Norbert J Liebsch; Francis J Hornicek; Saveli Goldberg; Henry Mankin; Andrew E Rosenberg; Daniel I Rosenthal; Herman D Suit Journal: Int J Radiat Oncol Biol Phys Date: 2006-06-06 Impact factor: 7.038
Authors: Christopher A Hulen; H Thomas Temple; William P Fox; Andrew A Sama; Barth A Green; Frank J Eismont Journal: J Bone Joint Surg Am Date: 2006-07 Impact factor: 5.284
Authors: Bruno Fuchs; Ian D Dickey; Michael J Yaszemski; Carrie Y Inwards; Franklin H Sim Journal: J Bone Joint Surg Am Date: 2005-10 Impact factor: 5.284
Authors: Richard S Pieters; Andrzej Niemierko; Barbara C Fullerton; John E Munzenrider Journal: Int J Radiat Oncol Biol Phys Date: 2005-07-01 Impact factor: 7.038
Authors: Nancy Y Lee; James G Mechalakos; Sadek Nehmeh; Zhixiong Lin; Olivia D Squire; Shangde Cai; Kelvin Chan; Pasquale B Zanzonico; Carlo Greco; Clifton C Ling; John L Humm; Heiko Schöder Journal: Int J Radiat Oncol Biol Phys Date: 2007-09-14 Impact factor: 7.038
Authors: Sadek A Nehmeh; Nancy Y Lee; Heiko Schröder; Olivia Squire; Pat B Zanzonico; Yusuf E Erdi; Carlo Greco; Gig Mageras; Hai S Pham; Steve M Larson; Clifton C Ling; John L Humm Journal: Int J Radiat Oncol Biol Phys Date: 2008-01-01 Impact factor: 7.038
Authors: Rene G C Santegoeds; Yasin Temel; Jan C Beckervordersandforth; Jacobus J Van Overbeeke; Christianne M Hoeberigs Journal: Curr Radiol Rep Date: 2018-04-03